© 2019 Kantum Pharma

Registered trademark of Kantum Pharma, Inc

Kantum's mission is to establish a new therapeutic paradigm

for AKI prevention and treatment.

DEDICATED TO THE PREVENTION AND TREATMENT OF ACUTE KIDNEY INJURY

Kantum Pharma founder to present preclinical data demonstrating beneficial effects of P2Y14 antagonist in Acute Kidney Injury at the American Society of Nephrology Annual Meeting.

 

Title:        The P2Y14 Receptor: Linking the Intercalated Cell to Immune Defense

Presenter:    Sylvie Breton, PhD, Professor of Medicine at Harvard Medical School

Time:        Thursday November 7, at 3:30pm

Location:     146 C, Walter E. Washington Convention Center

Click here to Learn More